CN106488770A - 用于治疗copd的福莫特罗和布***的组合 - Google Patents

用于治疗copd的福莫特罗和布***的组合 Download PDF

Info

Publication number: CN106488770A
Authority: CN; China
Prior art keywords: composition; formoterol; copd; protection; budesonide
Prior art date: 2014-05-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201580024895.5A

Other languages

English (en)

Chinese (zh)

Inventor

M·乌尔曼

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teva Pharmaceutical Europe LLC

Original Assignee

Teva Pharmaceutical Europe LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-12

Filing date

2015-05-08

Publication date

2017-03-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51032625&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106488770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-08 Application filed by Teva Pharmaceutical Europe LLC filed Critical Teva Pharmaceutical Europe LLC

2017-03-08 Publication of CN106488770A publication Critical patent/CN106488770A/zh

Status Pending legal-status Critical Current

Links

BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title claims abstract description 16
229960002848 formoterol Drugs 0.000 title claims abstract description 16
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title claims abstract description 9
229960004436 budesonide Drugs 0.000 title claims abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 37
206010010264 Condition aggravated Diseases 0.000 claims abstract description 18
238000012423 maintenance Methods 0.000 claims abstract description 15
238000011282 treatment Methods 0.000 claims abstract description 15
229940127558 rescue medication Drugs 0.000 claims abstract description 12
238000011866 long-term treatment Methods 0.000 claims abstract description 8
230000009798 acute exacerbation Effects 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 5
239000003814 drug Substances 0.000 claims description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
239000008101 lactose Substances 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 4
229960000193 formoterol fumarate Drugs 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
238000009472 formulation Methods 0.000 claims description 2
OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 24
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 16
229940080593 budesonide / formoterol Drugs 0.000 description 11
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
239000012190 activator Substances 0.000 description 9
239000002245 particle Substances 0.000 description 9
239000003246 corticosteroid Substances 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 7
208000024891 symptom Diseases 0.000 description 6
229960001375 lactose Drugs 0.000 description 4
238000000034 method Methods 0.000 description 4
RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical group O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010013975 Dyspnoeas Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000007789 gas Substances 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
238000011262 co‐therapy Methods 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
229960004017 salmeterol Drugs 0.000 description 2
238000009118 salvage therapy Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000004704 ultra performance liquid chromatography Methods 0.000 description 2
208000020053 Abnormal inflammatory response Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
241001602876 Nata Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
BPZSYCZIITTYBL-ORAYPTAESA-N S-formoterol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-ORAYPTAESA-N 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000003915 air pollution Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960002714 fluticasone Drugs 0.000 description 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
150000004675 formic acid derivatives Chemical class 0.000 description 1
229940021598 formoterol and budesonide Drugs 0.000 description 1
229960003610 formoterol fumarate dihydrate Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
-1 hydrobromate Chemical compound 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000002969 morbid Effects 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
229940124624 oral corticosteroid Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
102220043159 rs587780996 Human genes 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CN201580024895.5A 2014-05-12 2015-05-08 用于治疗copd的福莫特罗和布***的组合 Pending CN106488770A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB1408387.7		2014-05-12
GBGB1408387.7A GB201408387D0 (en)	2014-05-12	2014-05-12	Treatment of respiratory disorders
PCT/EP2015/060257 WO2015173154A1 (en)	2014-05-12	2015-05-08	Combinations of fomoterol and budesunide for the treatment of copd

Publications (1)

Publication Number	Publication Date
CN106488770A true CN106488770A (zh)	2017-03-08

Family

ID=51032625

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201580027124.1A Pending CN106470700A (zh)	2014-05-12	2015-05-08	用于治疗copd的噻托溴铵、福莫特罗和布***的组合
CN201580024895.5A Pending CN106488770A (zh)	2014-05-12	2015-05-08	用于治疗copd的福莫特罗和布***的组合

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CN201580027124.1A Pending CN106470700A (zh)	2014-05-12	2015-05-08	用于治疗copd的噻托溴铵、福莫特罗和布***的组合

Country Status (17)

Country	Link
US (2)	US20170209464A1 (pt)
EP (2)	EP3142653A1 (pt)
JP (4)	JP2017515833A (pt)
KR (2)	KR20170003601A (pt)
CN (2)	CN106470700A (pt)
AR (2)	AR100369A1 (pt)
AU (2)	AU2015261104A1 (pt)
BR (2)	BR112016026371A2 (pt)
CA (2)	CA2948553A1 (pt)
CL (1)	CL2016002848A1 (pt)
EA (2)	EA201692278A1 (pt)
GB (1)	GB201408387D0 (pt)
IL (2)	IL248874A0 (pt)
MX (2)	MX2016014695A (pt)
PE (1)	PE20170073A1 (pt)
UA (2)	UA119774C2 (pt)
WO (2)	WO2015173153A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104758294A (zh) *	2014-12-17	2015-07-08	广州呼吸疾病研究所	用于copd、哮喘治疗的吸入药物组合物及其制备方法
WO2017108917A1 (en) *	2015-12-22	2017-06-29	Astrazeneca Ab	Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
CN106466322A (zh) *	2016-08-25	2017-03-01	杭州百诚医药科技股份有限公司	一种以布***和噻托溴铵为活性成分的复方制剂
WO2018071445A1 (en) *	2016-10-11	2018-04-19	Microdose Therapeutx, Inc.	Inhaler and methods of use thereof
WO2019142214A1 (en)	2018-01-19	2019-07-25	Cipla Limited	Pharmaceutical composition comprising tiotropium for inhalation
JP2021513901A (ja) *	2018-02-23	2021-06-03	マイクロドースセラピューテクス，インコーポレイテッド	吸入器およびその使用方法
CN116077471A (zh) *	2021-11-08	2023-05-09	上海臣邦医药科技股份有限公司	一种供吸入用的粉雾剂组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1271287A (zh) *	1997-09-19	2000-10-25	阿斯特拉公司	布***和福莫特罗的新用途
US20050042175A1 (en) *	2003-06-19	2005-02-24	Microdrug Ag	Combined doses of formoterol and budesonide
EP2682102A2 (en) *	2012-07-05	2014-01-08	Sanovel Ilac Sanayi ve Ticaret A.S.	Inhalation Compositions Comprising Corticosteroid and Sorbitol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0613371B1 (en) *	1991-12-18	2002-03-06	AstraZeneca AB	New combination of formoterol and budesonide
AU673660C (en) *	1991-12-18	2002-07-25	Astrazeneca Ab	New combination of formoterol and budesonide
SE9802073D0 (sv) *	1998-06-11	1998-06-11	Astra Ab	New use
DE10130371A1 (de) *	2001-06-23	2003-01-02	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
UA80123C2 (en) *	2002-04-09	2007-08-27	Boehringer Ingelheim Pharma	Inhalation kit comprising inhalable powder of tiotropium
US20070293460A1 (en) *	2005-10-31	2007-12-20	Richie's Pharmacy And Medical Supply, Incorporated	Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
EP2049086A2 (en) *	2006-08-09	2009-04-22	Glaxo Group Limited	Process for manufacturing lactose
EP2124915A2 (en) *	2007-02-19	2009-12-02	Cipla Limited	Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
KR20100063116A (ko) *	2007-09-12	2010-06-10	글락소 그룹 리미티드	치료제들의 복합제
TR201000680A2 (tr) *	2010-01-29	2011-08-22	B�Lg�� Mahmut	Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
PL2560611T3 (pl) *	2010-04-21	2018-05-30	Chiesi Farmaceutici S.P.A.	Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych
US20130274232A1 (en) *	2010-07-16	2013-10-17	Cipla Limited	Pharmaceutical Compositions
JOP20120023B1 (ar) *	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
RU2460547C1 (ru) *	2011-04-08	2012-09-10	Валерий Феофанович Ушаков	Способ пролонгированной профилактики холодового бронхоспазма у больных с "микст-патологией"
ITMI20130571A1 (it) *	2013-04-10	2014-10-11	Zambon Spa	Composizione farmaceutica contenente budesonide e formoterolo

2014
- 2014-05-12 GB GBGB1408387.7A patent/GB201408387D0/en not_active Ceased
2015
- 2015-05-08 CA CA2948553A patent/CA2948553A1/en not_active Abandoned
- 2015-05-08 EA EA201692278A patent/EA201692278A1/ru unknown
- 2015-05-08 JP JP2016567345A patent/JP2017515833A/ja active Pending
- 2015-05-08 EP EP15722174.8A patent/EP3142653A1/en not_active Withdrawn
- 2015-05-08 EA EA201692276A patent/EA201692276A1/ru unknown
- 2015-05-08 EP EP15723675.3A patent/EP3142654A1/en not_active Withdrawn
- 2015-05-08 KR KR1020167033456A patent/KR20170003601A/ko not_active Application Discontinuation
- 2015-05-08 CA CA2948574A patent/CA2948574A1/en not_active Abandoned
- 2015-05-08 WO PCT/EP2015/060256 patent/WO2015173153A1/en active Application Filing
- 2015-05-08 MX MX2016014695A patent/MX2016014695A/es unknown
- 2015-05-08 CN CN201580027124.1A patent/CN106470700A/zh active Pending
- 2015-05-08 CN CN201580024895.5A patent/CN106488770A/zh active Pending
- 2015-05-08 PE PE2016002160A patent/PE20170073A1/es unknown
- 2015-05-08 KR KR1020167033449A patent/KR20170003600A/ko not_active Application Discontinuation
- 2015-05-08 US US15/310,130 patent/US20170209464A1/en not_active Abandoned
- 2015-05-08 BR BR112016026371-5A patent/BR112016026371A2/pt not_active Application Discontinuation
- 2015-05-08 MX MX2016014696A patent/MX2016014696A/es unknown
- 2015-05-08 UA UAA201612511A patent/UA119774C2/uk unknown
- 2015-05-08 JP JP2016567354A patent/JP2017515835A/ja active Pending
- 2015-05-08 US US15/310,133 patent/US20170202858A1/en not_active Abandoned
- 2015-05-08 AU AU2015261104A patent/AU2015261104A1/en not_active Abandoned
- 2015-05-08 AU AU2015261103A patent/AU2015261103A1/en not_active Abandoned
- 2015-05-08 UA UAA201612510A patent/UA119773C2/uk unknown
- 2015-05-08 BR BR112016026369-3A patent/BR112016026369A2/pt not_active Application Discontinuation
- 2015-05-08 WO PCT/EP2015/060257 patent/WO2015173154A1/en active Application Filing
- 2015-05-11 AR ARP150101432A patent/AR100369A1/es unknown
- 2015-05-11 AR ARP150101431A patent/AR100368A1/es unknown
2016
- 2016-11-09 IL IL248874A patent/IL248874A0/en unknown
- 2016-11-09 IL IL248875A patent/IL248875A0/en unknown
- 2016-11-09 CL CL2016002848A patent/CL2016002848A1/es unknown
2019
- 2019-10-11 JP JP2019187349A patent/JP2020023536A/ja not_active Withdrawn
- 2019-10-11 JP JP2019187350A patent/JP2020023537A/ja not_active Withdrawn

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1271287A (zh) *	1997-09-19	2000-10-25	阿斯特拉公司	布***和福莫特罗的新用途
US20050042175A1 (en) *	2003-06-19	2005-02-24	Microdrug Ag	Combined doses of formoterol and budesonide
EP2682102A2 (en) *	2012-07-05	2014-01-08	Sanovel Ilac Sanayi ve Ticaret A.S.	Inhalation Compositions Comprising Corticosteroid and Sorbitol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASTRAZENECA: "布**福莫特罗粉吸入剂说明书", 《药智数据-药品说明书》
BJORN STALLBERG等: "Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised，non-inferiority, parallel-group, multicentre study", 《RESPIRATORY RESEARCH》 *

Also Published As

Publication number	Publication date
CA2948553A1 (en)	2015-11-19
JP2017515833A (ja)	2017-06-15
BR112016026369A2 (pt)	2018-05-15
JP2020023537A (ja)	2020-02-13
CN106470700A (zh)	2017-03-01
AU2015261103A1 (en)	2016-11-17
KR20170003601A (ko)	2017-01-09
US20170209464A1 (en)	2017-07-27
GB201408387D0 (en)	2014-06-25
WO2015173154A1 (en)	2015-11-19
PE20170073A1 (es)	2017-03-24
CL2016002848A1 (es)	2017-07-07
AR100369A1 (es)	2016-09-28
WO2015173154A9 (en)	2016-03-03
MX2016014696A (es)	2017-05-04
EA201692278A1 (ru)	2017-02-28
IL248874A0 (en)	2017-01-31
CA2948574A1 (en)	2015-11-19
KR20170003600A (ko)	2017-01-09
EA201692276A1 (ru)	2017-03-31
EP3142653A1 (en)	2017-03-22
US20170202858A1 (en)	2017-07-20
MX2016014695A (es)	2017-05-04
AR100368A1 (es)	2016-09-28
EP3142654A1 (en)	2017-03-22
WO2015173153A1 (en)	2015-11-19
UA119773C2 (uk)	2019-08-12
IL248875A0 (en)	2017-01-31
JP2017515835A (ja)	2017-06-15
JP2020023536A (ja)	2020-02-13
UA119774C2 (uk)	2019-08-12
BR112016026371A2 (pt)	2018-06-19
AU2015261104A1 (en)	2016-11-17

Legal Events

Date	Code	Title	Description
2017-03-08	C06	Publication
2017-03-08	PB01	Publication
2017-06-06	SE01	Entry into force of request for substantive examination
2017-06-06	SE01	Entry into force of request for substantive examination
2018-01-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1232787 Country of ref document: HK
2021-01-29	WD01	Invention patent application deemed withdrawn after publication
2021-01-29	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20170308
2023-12-01	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1232787 Country of ref document: HK

Publication	Publication Date	Title
CN106488770A (zh)	2017-03-08	用于治疗copd的福莫特罗和布***的组合
Hvizdos et al.	2000	Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders
US8834848B2 (en)	2014-09-16	Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma
CN103476412B (zh)	2017-07-14	用于改善呼吸***疾病患者睡眠质量的阿地铵
EP3148521A1 (en)	2017-04-05	Fluticasone furoate in the treatment of copd
CN101657191B (zh)	2014-06-11	包括福莫特罗和二丙酸倍氯米松的组合物在制备用于预防和/或治疗哮喘恶化的药物中的用途
ZuWallack et al.	2010	Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI
CN102416179A (zh)	2012-04-18	用于哮喘的吸入性复方组合物
TWI436761B (zh)	2014-05-11	使用噻唑衍生物之方法
US20100136121A1 (en)	2010-06-03	Medicaments
CN107106516A (zh)	2017-08-29	药物组合产品
Thamby et al.	2012	Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia
Escribano et al.	2006	Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial
CN115989032A (zh)	2023-04-18	用于吸入施用的组合疗法
Meek et al.	2006	Selection of aerosol delivery device
US20140011784A1 (en)	2014-01-09	Method and composition for treating asthma
CN110664819A (zh)	2020-01-10	供吸入的齐墩果酸制剂及其制备方法与医药用途
Yerbury et al.	2007	3 Symptom Management
Dickinson et al.	2016	GENERAL PRINCIPLES Definition
US20130125882A1 (en)	2013-05-23	Method and composition for treating asthma and copd